Document is current
Any future updates will be listed below
-
Authors
Fallowfield, L.
Starkings, R.
Palmieri, C.
Tait, A.
Stephen, L.
May, S.
Habibi, R.
Russ, S.
Shilling, V.
Jenkins, V.
-
Funding
Funding for this research was provided by:
Make2ndsCount, Edinburgh (G3352)
Make2ndsCount, Edinburgh (G3352)
Make2ndsCount, Edinburgh (G3352)
- License Information
-
More Information
Article History
Received: 24 April 2023
Accepted: 2 July 2023
First Online: 11 July 2023
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Brighton & Sussex Research Ethics Committee (BSMS RGEC; ER/RMLS21/7).
: Informed consent was obtained from all individual participants included in the study.
: LJF, V and CP were awarded a grant from Make2ndsCount Charity to conduct the research. AT is a patient representative, and LS is a Trustee for Make2ndsCount and patient advocate. CP has grant funding from Pfizer and Daiichi Sankyo and honoraria from Pfizer, Roche, Daiichi Sankyo, Novartis, Exact sciences, Gilead, SeaGen and Eli Lilly. All other authors have no conflicts of interest to declare.
: The Charity had no role in the collection, analysis or interpretation of the data or in the writing of the manuscript.
